Old age is accompanied by an increased likelihood of illness, and old people take a disproportionate amount of selfadministered and prescribed medications. In the USA, people over 65 consume 30% of prescriptions and 40% of over-the-counter remedies, despite making up only 13% of the population 1 . In the UK, elderly people comprise only 18% of the population but use 45% of all prescription drugs, some of which are prescribed inappropriately and without proper attention to side-effects 2 . Elderly people living in nursing homes are even more likely to receive medications and to experience side-effects 3 . Thus, in one year, 97% of elderly nursing home residents received a prescription drug, compared with 71% of patients living in the community 4 . Failure to identify side-effects can lead to use of other drugs to treat the symptoms, rather than adjustment of the dose of the drug responsible.
mode of action (e.g. drugs for parkinsonism, irritable bowel syndrome, urinary incontinence) and others with unwanted anticholinergic effects. Tune et al. 7 looked for in-vitro anticholinergic activity in the 25 drugs most commonly prescribed for elderly people and found such activity in 14 (Table 1) . Often, elderly patients receive several such drugs simultaneously. Many non-prescription drugs have anticholinergic potential; this is true of the antihistamines in cold/¯u and hayfever treatmentsÐe.g. diphenhydramine (Benylin Four Flu); triprolidine (Actifed); chlorpheniramine (Piriton/ Contact 400); and promethazine (Night Nurse/Phenergan). Skin creams and lotions also contain antihistaminesÐe.g. diphenhydramine (Allereze cream) or mepyramine (Anthisan)Ðand treatments for sleep disturbance include diphenhydramine (Nightcalm/Nytol) and promethazine (Sominex/Phenergan). Some hayfever medications contain theophylline (e.g. Chest-Eze), antidiarrhoeals include extract of belladonna (Enterosan, Opazimes) and some treatments for irritable bowel syndrome contain hyoscine (Buscopan).
The number of drugs with anticholinergic potential available without prescription is increasing 6 , so that the use of such medications is becoming more dif®cult to monitor. For example, histamine H 2 antagonists can be had over the counter for indigestionÐcimetidine (Tagamet/Acid-eze); ranitidine (Zantac); famotidine (Pepcid AC). Of those drugs examined by Tune et al. 7 , cimetidine had the highest anticholinergic activity in vitro, although side-effects attributed to this activity do not feature in the labelling of cimetidine. One interpretation is that in-vitro pharmacological activity does not always predict clinical effects; alternatively, the activity reported by Tune et al., though insuf®cient to cause obvious side-effects with cimetidine monotherapy in young adults, might be troublesome in those already receiving anticholinergic medications or otherwise vulnerable. High doses of cimetidine in elderly patients have occasionally been associated with reversible confusional states (confusion, delirium, slurred speech, hallucinations, coma 8 ).
RECOGNIZING ANTICHOLINERGIC SIDE-EFFECTS
Symptoms which may be caused by drugs with anticholinergic activity include:
. Dry or sticky lips; dif®culty beginning to speak (need to lick lips ®rst) . Urinary disorders, necessitating use of catheter . Skin dry, pale and cool . Insecure movement; falls without obvious reason, blurred vision . Increased anxiety, with rapid, shallow breathing, tachycardia, cardiac arrhythmias.
Anticholinergic actions affect multiple systems, causing a range of peripheral and central side-effects and symptoms ( Table 2 ). Central anticholinergic effects include memory de®cits, confusion and disorientation, agitation, hallucinations and delirium 4,6 . In the extreme, anticholinergic toxicity depresses brain function, with coma and circulatory collapse.
IMPACT OF ANTICHOLINERGIC SIDE-EFFECTS
Why should old people be at increased risk of anticholinergic side-effects 4, 9 ? Part of the reason may lie in de®cient drug metabolism and elimination, as well as agerelated de®cits in cholinergic neurotransmission 6 . For people living in nursing homes, with little to distract them, side-effects can be particularly distressing and dif®cult to cope with. For example, dry mouth, while apparently trivial, can cause speech dif®culties, dental decay or trouble with dentures. Chewing and swallowing may become painful, and the patient may refuse solid food. The pain of dry mouth can be extremely distressing for older patients, who may become frustrated and agitated by an inability to communicate their distress.
Older people often have multiple illnesses. In the USA as many as ®ve chronic conditions in one person is not unusual 10 , and conditions such as angina, congestive heart failure, constipation, diabetes mellitus, glaucoma, urinary dysfunction, sleep disturbance and dementia are all worsened by drugs with anticholinergic activity 6 . Pupillary dilatation and the inability to accommodate will impair near vision, thus increasing the risk of accidents, including falls,
V o l u m e 9 3 S e p t e m b e r 2 0 0 0 Delirium can be caused by blockade of brain muscarinic receptors; drugs with anticholinergic activity are the most common cause of drug-induced delirium 7, 11 . More than one-®fth of elderly patients admitted to hospital develop delirium, particularly those with dementia and multiple illnesses. In patients with dementia, anticholinergic drugs further inhibit cognitive performance and counteract the bene®cial effects of cholinergic enhancers used to treat cognitive impairment.
Williamson et al. 9 examined the use of psychotropics and antiparkinsonian drugs (both have marked anticholinergic effects) in nearly 2000 patients admitted to geriatric units. More than a quarter were receiving one such drug, and 13% of those patients had signi®cant adverse events 6 . Nevertheless, physicians often attribute anticholinergic symptoms in elderly people to ageing or agerelated illness rather than the effects of drugs 6 . Even physicians and carers who appreciate that such symptoms can be drug-induced may regard them as inevitable, simply because they are so common.
UNDERSTANDING THE RISK: POLYPHARMACY AND`ANTICHOLINERGIC LOAD'
In their nursing home study, Blazer et al. 4 calculated that between 21% and 32% of residents could have been taking two or more drugs with anticholinergic activity (three or more drugs 10±17% of patients; ®ve or more drugs, up to 5%). The most common combinations were thioridazine/ benzhexol and thioridazine/chlorpromazine (benzhexol is now seldom used). However, combined use of thioridazine and amitriptyline (each with marked anticholinergic activity) was also very common, demonstrating a lack of concern about combined anticholinergic effects.
Partly through legislation, there have been reductions in the use in US nursing homes of psychotropic drugs, many of which have marked anticholinergic activity 12 treating patients in nursing homes 13 . With increasing use of newer psychotropics anticholinergic side-effects in elderly people may be declining, but many different drugs have some anticholinergic activity and elderly patients receiving multiple drugs are still at risk of`anticholinergic load' 14 . In theory the physician can predict the anticholinergic load and the risk of side-effects associated with any combination of drugs. In practice, the information available from the product label and from the published work focuses on sideeffects of drugs used as monotherapy. The concept of anticholinergic load illustrates that side-effects can be caused by combinations of drugs, even if the individual drugs do not cause obvious side-effects.
PSYCHOTROPIC DRUGS: THE MAJOR BURDEN
These are among the most common medications taken by elderly people living in nursing homes (mainly antipsychotics, antidepressants and anxiolytics/sedatives). Spore et al. 15 found that 43% of elderly patients in residential care were receiving psychotropic drugs. Antidepressants and antipsychotics have been linked most often with disorders due to anticholinergic activity.
Antidepressants
The use of antidepressants in elderly people requires particular care 16, 17 . Tricyclic antidepressants (TCAs) have been in use for over 30 years, and imipramine and amitriptyline are the standard against which new drugs are evaluated. Old patients are more likely than young adults to experience side-effects with TCAs (see Box 1 for examples). Apart from the postural hypotension and sedation associated with the TCAs, anticholinergic sideeffects such as constipation, urinary retention and confusion are particular causes for concern. Some authorities have advised against the use of TCAs such as imipramine, amitriptyline and doxepin in the elderly because of their side-effects, not least their anticholinergic effects 18±20 . Nortriptyline, lofepramine and desipramine (the least anticholinergic of the TCAs) tend to be better tolerated. Some newer antidepressants may be useful alternatives to TCAs in elderly people 21 . The selective serotonin reuptake inhibitors such as¯uoxetine and sertraline have been recommended, partly because of their relative freedom from anticholinergic side-effects 19, 20 . Nefazodone, bupropion, venlafaxine and mirtazapine also have less anticholinergic potential than the older drugs 22 .
Antipsychotics
Conventional neuroleptic drugs are widely used in the treatment of behavioural and psychological symptoms of dementia 23±25 , despite a lack of prospective placebocontrolled studies on their use in these circumstances 26 . Substantial differences exist between conventional neuroleptic drugs with respect to anticholinergic activity; chlorpromazine and thioridazine have the highest activity 27, 28 with considerable side-effects 29 (see Box 1). Haloperidol has lower muscarinic af®nity and the risk of anticholinergic side-effects is lower, but extrapyramidal symptoms are more troublesome 29 . Conventional neuroleptic drugs can also cause other side-effects. Low doses have been recommended for elderly patients, although this may limit the ef®cacy of these agents 26 .
Novel antipsychotic drugs have been widely studied in younger patients (particularly those with schizophrenia), but for most drugs no controlled trials have been reported in elderly patients 26 . An exception is risperidone, which has been compared with placebo in two trials in elderly nursing home patients with dementia 30, 31 . Risperidone is the only novel antipsychotic so far registered for this indication in certain countries (though not in the UK). It has no measurable anticholinergic activity 28 and has not been reported to cause anticholinergic side-effects in elderly patients 30, 31 . By contrast, clozapine has marked anticholinergic activity and is associated with profound anticholinergic side-effects 32±34 . When clozapine (and other antipsychotics with high anticholinergic activity) are withdrawn, two types of withdrawal reaction are seenÐ cholinergic rebound', with nausea, vomiting, loss of appetite, malaise, diarrhoea, rhinorrhoea, sweating, anxiety, agitation and insomnia 35, 36 ; and movement disorders such as dyskinesia, akathisia and parkinsonism 37 . When switching patients to a drug with low anticholinergic potential, physicians sometimes mistake withdrawal symptoms for the side-effects of the new drug.
CHANGING PRESCRIBING PRACTICE
Physicians should be alert to the possibility that dry mouth, constipation and blurred vision may be caused by medication. Changes in intellectual function should also be investigated, especially in patients who already have cognitive impairment. For patients in whom side-effects can have particularly unpleasant consequences (e.g. those with gastrointestinal disease, bladder neck obstruction, glaucoma, cardiac disease or cognitive impairment), serious consideration should be given to switching to a drug that lacks anticholinergic side-effects.
For most drugs with anticholinergic potential an alternative is available. Combinations of drugs with strong anticholinergic activity, such as thioridazine and amitriptyline, should obviously be avoided. The use of drugs with minimal anticholinergic activity from the outset should avoid the need to switch medication (and the risk of cholinergic rebound). If switching is necessary, the hazard of rebound can be lessened by slowly tapering the doses, with additional anticholinergic medication if necessary 38 . For patients already receiving treatment, the current anticholinergic load should always be considered before another drug is introduced. If the current load is high, even drugs with moderate or low anticholinergic activity may precipitate side-effects. No drug should be introduced without careful assessment of existing medications and symptoms. Often, there is little published information on the complex combinations of drugs used in elderly people. In-vitro activity can only be a broad predictor of clinical effects, and information from clinical trials may likewise be of limited value; for example, so far, trials of antipsychotic drugs in elderly people have not speci®cally inquired about anticholinergic side-effects but have relied on spontaneous reporting by patients or carers. The range and severity of side-effects may therefore have been underestimated.
INFORMING PATIENTS AND CARERS
Informing patients and carers about potential side-effects is of great importance. Dif®culties with side-effects are likely to result in poorer treatment outcomes and are a major cause of non-compliance. If patients and carers are sensitively informed about unwanted effects, this will help to reduce the anxiety and distress that side-effects may cause.
PHYSICAL MEASURES
When anticholinergic side-effects do occur and the drug cannot be stopped, some steps can be taken to reduce their impact on the patient. The discomfort of dry mouth can be reduced by taking sips of water, or by chewing sugarless gum or soft sweets, while arti®cial tears are useful for dry eyes. Pilocarpine solution has been used as a mouthwash for dry mouth or as eye drops for blurred vision 39, 40 . Constipation can be reduced by high-®bre diets, ®bre supplements, increased¯uid intake or greater patient mobility (e.g. walking down the ward to meals). Oral bethanechol, a cholinergic agonist, has been used to treat anticholinergic effects but can itself cause tremor, diarrhoea and abdominal cramps 39 . Furthermore, treatment of drug side-effects with another drug is not good practice; a much better strategy is to prescribe a medication relatively free from side-effects.
